Despite progress in the successful treatment of patients with rheumatoid arthritis (RA) who are using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), a Greek study has found that a considerable number of patients are still not achieving low disease activity (LDA) despite having been treated following established recommendations for RA therapy.
Despite progress in the successful treatment of patients with rheumatoid arthritis (RA) who are using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), a Greek study has found that a considerable number (20.9%) of patients are still not achieving low disease activity (LDA) despite having been treated following established recommendations for RA therapy.
The study was published in the June 15, 2018, issue of the Annals of the Rheumatic Diseases.1
The data from the study are based on the experience of 538 patients at a Greek outpatient RA clinic who were followed from January 2006 to December 2017. All patients fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for early RA, had disease duration for less than 1 year, were csDMARD- and bDMARD-naïve, and were treated according to EULAR/ACR recommendations and strategies for RA.
The csDMARDs used to treat patients were:
The following bDMARDs were used:
Small doses of steroids were also administered. During follow up, laboratory findings, treatment decisions and strategies, any drug reactions, and reasons for termination or changes in treatment strategies were recorded. Disease activity was measured with the Disease Activity Score-28 (DAS-28) using the erythrocyte sedimentation rate.
All patients received 1 csDMARD for at least 6 months. The csDMARD of first choice was MTX (58%), followed by LFN (32%), HCQ (8%), and SSZ (2%); the bDMARD of first choice was INF (37%) followed by ETN (32%) and ADA (31%). Seven patients never received bDMARDs because of comorbidities.
The final results were based on data from 517 patients (14 patients were lost; 7 never received bDMARDs). Among the remaining 517 patients, 324 patients (66%) were treated with csDMARDs as monotherapy or in combination, with or without steroids, with significant clinical improvement and sustained low-disease activity (LDA). However, 11 patients (3.2%) from this group neither achieved LDA nor received bDMARDs due to comorbidities. A total of 175 (34%) patients were treated with bDMARDs with or without csDMARDs and/or steroids and the majority demonstrated sustained LDA for a long period of time. Of this group, 31 patients (17.7%) never achieved LDA despite switching and receiving all bDMARDs. Thus, a total of 20.9% of the patients never achieved LDA.
The researchers conclude that their real-life study estimates the significant size of the unmet need among patients with RA despite adherence to established ACR/EULAR—endorsed treatment methods.
Reference
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.